Compare PXED & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | GLUE |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2025 | 2021 |
| Metric | PXED | GLUE |
|---|---|---|
| Price | $31.78 | $23.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $45.00 | $19.50 |
| AVG Volume (30 Days) | 142.8K | ★ 1.2M |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.51 | 0.25 |
| Revenue | ★ $1,007,192,000.00 | $181,538,000.00 |
| Revenue This Year | $4.15 | $84.02 |
| Revenue Next Year | $4.86 | N/A |
| P/E Ratio | ★ $9.74 | $63.42 |
| Revenue Growth | 6.02 | ★ 1112.27 |
| 52 Week Low | $23.52 | $3.50 |
| 52 Week High | $47.08 | $19.17 |
| Indicator | PXED | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 72.64 |
| Support Level | N/A | $13.69 |
| Resistance Level | N/A | $17.81 |
| Average True Range (ATR) | 0.00 | 1.55 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 0.00 | 83.64 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.